KRAS and cancer: The receptor tyrosine kinase/RAS/MAP kinase (MAPK) pathway is an oncogenic pathway with widespread aberrancies in human cancers; indeed, 20%-30% of cancer patients harbor RAS (KRAS, HRAS, or NRAS) mutations.